Table 5.

2014 SOSS High Priority Trials

Committee	Priority
Leukemia	Phase III study of postallogeneic transplantation maintenance using FLT3 inhibition versus placebo in patients with FLT3+ AML and azacytidine versus placebo in those with FLT3-AML
Lymphoma	Phase III study of postautologous transplantation maintenance using ibrutinib versus placebo in patients with relapsed or refractory DLBCL
Nonmalignant disease	Phase III study of autologous transplantation versus standard therapy for MS
Pediatric indications	Phase III study of post-transplantation maintenance using moxetumomab or inotuzumab versus placebo in pediatric and adult patients with B cell ALL
Pediatric outcomes	Phase II study of daily versus alternate day dosing of steroids for chronic GVHD
Optimal donor and graft source	Phase II study of haploidentical peripheral blood stem cells and PTCY after myeloablative conditioning
GVHD	In low-risk patients, randomized phase II studies of novel agents versus steroids, and in high-risk patients, randomized phase II studies of novel agents plus steroids versus steroids alone
Gene and cell therapy	Phase III study of haploidentical donor NK cells for AML
Comorbidity/RRT	Development of a more robust risk assessment method incorporating biomarkers and geriatric assessment tools
Infection/immune reconstitution	Phase III study of CMV-specific T cell adoptive therapy.
Infection/immune reconstitution	Phase II study of a novel PIV entry inhibitor in HCT recipients with upper respiratory tract infection
Late effects	Phase III randomized trial of zoledronic acid versus placebo for prevention of bone loss after allogeneic HCT